Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.20M | $21.1M | $34.2M | $54.7M | $62.9M | $38.4M | $47.6M | $65.5M | $53.4M | $52.7M |
| Revenue growth | — | 129.1% | 62.4% | 59.7% | 15.0% | -39.0% | 24.2% | 37.5% | -18.5% | -1.2% |
| Gross profit | $801K | $4.01M | — | — | — | — | — | — | — | — |
| Gross margin | 8.7% | 19.0% | — | — | — | — | — | — | — | — |
| Operating income | -$33.2M | -$34.5M | -$19.3M | -$10.7M | $2.71M | -$20.5M | -$13.0M | $10.5M | $3.92M | -$5.50M |
| Operating margin | -360.5% | -163.8% | -56.4% | -19.6% | 4.3% | -53.4% | -27.3% | 16.0% | 7.3% | -10.4% |
| Net income | -$29.4M | -$83.4M | -$26.5M | -$18.3M | -$6.52M | -$27.6M | -$14.9M | $8.31M | $2.93M | -$6.60M |
| Net margin | -319.2% | -395.9% | -77.3% | -33.4% | -10.4% | -71.9% | -31.3% | 12.7% | 5.5% | -12.5% |
| EPS (diluted) | -$0.29 | -$6.37 | -$1.80 | -$1.23 | -$0.22 | -$0.62 | -$0.31 | $0.09 | $0.04 | -$0.08 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.1M | -$9.99M | -$7.74M | -$19.4M | -$26.1M | -$10.3M | -$25.0M | -$1.32M | $8.67M | -$12.0M |
| Capital expenditures | $849K | $971K | $686K | $627K | $655K | $1.46M | $628K | $1.15M | $1.28M | $1.64M |
| Free cash flow | -$32.9M | -$11.0M | -$8.43M | -$20.0M | -$26.8M | -$11.7M | -$25.6M | -$2.47M | $7.39M | -$13.6M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $63.3M | $51.2M | $37.8M | $17.8M | $18.3M | $39.0M | $17.1M | $23.6M | $19.8M | $14.7M |
| Total assets | $82.2M | $72.2M | $61.1M | $45.4M | $67.9M | $73.7M | $55.8M | $84.4M | $73.4M | $82.3M |
| Total liabilities | $92.2M | $102M | $114M | $116M | $95.0M | $79.7M | $66.4M | $50.9M | $30.2M | $34.1M |
| Shareholders' equity | -$9.96M | -$29.5M | -$52.9M | -$70.3M | -$27.0M | -$6.04M | -$10.6M | $33.6M | $43.2M | $48.2M |
| Retained earnings | -$213M | -$296M | -$323M | -$341M | -$347M | -$375M | -$390M | -$382M | -$378M | -$385M |
| Shares (wtd avg diluted) | 124M | 144M | 14.8M | 14.8M | 29.1M | 44.1M | 48.5M | 82.4M | 81.1M | 78.5M |
Every figure is extracted from Protalix BioTherapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.